Products

DM-Density
Densitas
Oncology AI
Densitas' DM-Density, now densitas densityai™, is an FDA-cleared AI software for automated and standardized breast density assessment from digital mammograms, aligning with ACR BI-RADS® Atlas 5th Edition.
densitas densityai
Densitas
Oncology AI
Densitas densityai™ is an AI-powered solution for automated and standardized breast density assessment from mammograms, aligning with ACR BI-RADS® guidelines to enhance consistency and support compliance in breast cancer screening.

See all 2 products →

About Densitas

Densitas is a healthcare AI company specializing in solutions for breast cancer screening, aiming to transform the mammography enterprise. Their core offering, intelliMammo™, is an AI-powered platform designed to enhance quality, safety, efficiency, and precision in breast health. For physicians, this platform provides automated tools for breast density assessment (densitas densityai™), clinical image quality evaluation (densitas qualityai™), and personalized breast cancer risk assessment (densitas riskai™).

The intelliMammo™ platform processes images automatically, delivering on-demand results at the point of care for radiological technologists and radiologists. It also offers retrospective analysis at clinic and health system levels through an advanced analytics platform, benefiting radiologists, quality control technologists, diagnostic imaging managers, and health system administrators. Their solutions are designed to support clinical decision-making, improve operational efficiencies, and ensure compliance with standards such as MQSA EQUIP and ACR BI-RADS density scale assessments, ultimately leading to better patient outcomes and tailored screening protocols.

Focus Areas

Breast cancer screening mammography quality breast density assessment breast cancer risk assessment operational efficiencies workflow optimization regulatory compliance (FDA MQSA EQUIP ACR accreditation) technologist training personalized breast health population health management AI in radiology

Business Intelligence

Key InvestorsInnovacorp, NSBI Venture Capital, Eldis Technologies, Anges Québec, MEDTEQ Invest, Real Ventures
PartnershipsMTMI (Medical Technology Management Institute), ACR Learning Network, iCAD, Intelerad Medical Systems, Nuance, Blackford, TungstenQI Partners, NorthShore University HealthSystem, Ikonopedia
TechnologyAI-powered platform utilizing machine learning and deep learning algorithms for digital mammography analysis. Products include intelliMammo (densityai, qualityai, riskai), intelliMaven (GPT AI assistant), and intelliRisk. The platform provides on-demand actionable insights at point-of-care and advanced analytics for various stakeholders in the mammography enterprise.
FDA ClearancesAt least 1 (DENSITAS|density, part of intelliMammo) cleared products (estimated)

What Physicians Need to Know

Breast Cancer Screening & Risk Assessment
Densitas specializes in enhancing breast cancer screening programs, offering advanced tools for breast density assessment and personalized breast cancer risk assessment. This aids in identifying high-risk patients and tailoring screening protocols.
Mammography Quality & Compliance
They focus on improving mammography quality and ensuring regulatory compliance, including FDA MQSA EQUIP and ACR accreditation. This helps clinics maintain high standards and avoid penalties.
Operational Efficiency & Workflow Optimization
Densitas provides solutions for optimizing operational efficiencies and streamlining workflows within radiology departments, leading to reduced administrative burden and improved throughput.
AI in Radiology & Technologist Training
A core specialization is the application of AI in radiology, particularly for mammography analysis. They also offer technologist training to ensure proper use of their tools and best practices.
Personalized & Population Health Management
Their offerings extend to personalized breast health strategies and tools for population health management, enabling a more targeted and effective approach to breast care across patient groups.
Physician Tip

For physicians, Densitas stands out by offering a comprehensive suite of AI-powered tools that directly address critical aspects of breast care. Their solutions can significantly improve diagnostic accuracy through objective breast density and risk assessment, streamline clinic operations by optimizing workflows, and ensure robust regulatory compliance. This translates to more confident diagnoses, reduced physician burnout from administrative tasks, and ultimately, better patient outcomes through personalized screening strategies and enhanced quality control. The focus on technologist training also ensures that the entire care team is proficient, leading to consistent, high-quality imaging.

While specific integration partners are not detailed in the provided information, Densitas's focus on workflow optimization and AI in radiology strongly implies their solutions are designed for seamless integration with existing PACS (Picture Archiving and Communication Systems), RIS (Radiology Information Systems), and EMR (Electronic Medical Record) platforms to ensure a cohesive and efficient clinical environment.

Products by Densitas

2 products in the directory

DM-Density
Densitas
Oncology AI
Densitas' DM-Density, now densitas densityai™, is an FDA-cleared AI software for automated and standardized breast density assessment from digital mammograms, aligning with ACR BI-RADS® Atlas 5th Edition.
densitas densityai
Densitas
Oncology AI
Densitas densityai™ is an AI-powered solution for automated and standardized breast density assessment from mammograms, aligning with ACR BI-RADS® guidelines to enhance consistency and support compliance in breast cancer screening.

What the Web Says

Densitas is a company that provides AI-powered solutions for breast cancer screening, focusing on mammography quality, breast density assessment, and high-risk patient tracking. Their products aim to automate routine tasks, improve diagnostic confidence for radiologists, and enhance operational efficiencies in breast health care. The company's software, such as densitas densityai, is FDA-cleared and integrates with existing PACS systems to provide standardized and reproducible breast density assessments.

Overall: Positive

Strengths

  • Automated, standardized, and reproducible breast density assessments.
  • Integrates seamlessly with existing PACS and enhances workflow.
  • Helps radiologists focus on more challenging interpretive tasks by automating routine ones.
  • Provides advanced analytics for benchmarking, monitoring, and trend detection in mammography quality.
  • Supports early identification of at-risk patients and informs follow-up care pathways.
  • Aids in improving positioning proficiency for mammography technologists.

Limitations

  • Limited publicly available employee reviews, making it difficult to assess overall employee satisfaction.
  • No job postings found, which could indicate limited growth or hiring activity.
  • Some general concerns about AI in radiology on Reddit, though not specific to Densitas, highlight a broader industry discussion about the role of AI and potential for misinformation.

Based on reviews from: Workopolis, Imaging Technology News, Densitas.health, Wellfound, YouTube, Reddit

Last updated: 2026-07-17

Videos

News, demos, and interviews about Densitas.

Loading videos...

Videos load interactively. If none appear, search YouTube for Densitas →

View all on YouTube

Press & Coverage

Densitas
Densitas Announces the Commercial Release of intelliMavenu2122: The First GPT AI Companion to Elevate Mammography Quality Standards.
Densitas commercially released intelliMavenu2122, a GPT AI assistant for mammography quality, on April 3rd, 2024. This new solution, alongside intelliMammou00ae, aims to provide scalable quality assurance for mammography facilities to meet regulatory and accreditation requirements.
2024-04
PR Newswire
Densitas: AI Identifies Persistent Mammography Positioning Challenges Impacting Screening Quality and Cancer Detection
A multicenter study published in the Journal of Breast Imaging on July 9, 2025, demonstrated that Densitas' intelliMammou00ae AI algorithms can identify persistent mammography positioning challenges. The study, analyzing over 126,000 mammograms, highlighted the AI's role in quantifying unmet positioning quality criteria across health systems.
2025-07
Densitas
Mount Sinai, Densitas and ACR ImPower Program Collaboration Increases the Quality of Mammography Positioning by 33%
On October 14, 2025, Densitas announced a collaboration with Mount Sinai Health System and the ACR ImPower Program, which resulted in a 33% increase in mammography positioning quality. This partnership aligns teams on standardized positioning criteria and reduces inter-technologist variability.
2025-10
PR Newswire
AI Meets QI: Densitas and TungstenQI Launch Joint Continuous Quality Improvement Initiative
Densitas and TungstenQI Partners announced a strategic partnership on April 22, 2025, to improve mammography positioning quality on a broad scale. This collaboration integrates Densitas' intelliMammou00ae platform with TungstenQI's expertise in quality frameworks.
2025-04
Densitas
Densitas Announces the Commercial Availability of intelliRisk, a High-Risk Breast Cancer Patient Management Platform.
Densitas announced the commercial availability of intelliRisku2122, its new high-risk breast cancer patient management platform, on March 20, 2025, following its debut at RSNA 2024. This platform aims to provide comprehensive and proactive management of high-risk patients.
2025-03
Densitas
Densitas Announces Strategic Collaboration with MTMI to Elevate Technologists' Performance in Mammography
On October 2, 2024, Densitas announced a strategic collaboration with the Medical Technology Management Institute (MTMI) to integrate MTMI's educational content into Densitas' intelliMammou00ae platform. This aims to elevate technologists' performance in mammography through improved clinical image quality.
2024-10
PR Newswire
Densitas Debuts intelliRisk, a High-Risk Breast Cancer Patient Management Platform
Densitas launched intelliRisku2122, a new high-risk breast cancer patient management platform, on November 13, 2024. This platform expands Densitas' capabilities in high-risk breast cancer patient management solutions, joining intelliMammou00ae and intelliMavenu2122.
2024-11
Imaging Technology News
Densitas Receives FDA Clearance for PACS-Centric Breast Density Software
On April 13, 2018, Densitas Inc. received U.S. Food and Drug Administration (FDA) clearance for its DENSITAS|density automated breast density software. This software analyzes processed digital mammograms stored in PACS to provide accurate breast density assessments.
2018-04

Frequently Asked Questions

Densitas's AI solutions, such as intelliMammou00ae and densityAIu2122, provide automated, objective breast density assessment aligned with ACR BI-RADSu00ae Atlas guidelines, which is crucial for personalized screening recommendations. They also offer quantitative quality metrics for mammography, helping to standardize image acquisition, reduce variability, and identify positioning challenges, leading to more accurate and consistent breast cancer screening.
Densitas offers a suite of AI-powered solutions including intelliMammou00ae, which comprises densityAIu2122 for automated breast density classification, and intelliRisku2122 for breast cancer risk assessment. These products are designed for seamless integration with existing PACS and RIS systems, minimizing disruption to current workflows and ensuring efficient data flow for comprehensive patient management.
By automating tasks like breast density assessment, image quality control, and compliance reporting, Densitas's solutions significantly reduce manual effort and technologist variability, freeing up staff for other critical duties. This automation streamlines the reading workflow, allows for immediate feedback on image quality, and helps optimize scheduling by reducing the need for repeat imaging due to technical errors.
Densitas's AI solutions, particularly intelliMammou00ae, provide objective, quantitative data on mammography quality and technologist performance, directly supporting compliance with FDA MQSA EQUIP guidelines and ACR accreditation standards. The automated reporting and consistent metrics streamline documentation, reduce review times, and enable closed-loop corrective action tracking, helping facilities demonstrate adherence to quality control protocols.
By providing accurate, individualized breast density and risk assessments (via densityAIu2122 and intelliRisku2122), Densitas enables clinicians to tailor screening protocols to individual patient risk profiles, moving towards personalized breast health. Aggregated data from their platforms can also inform population health strategies, identifying at-risk groups, optimizing resource allocation, and ensuring targeted follow-up for broader public health impact.
Densitas emphasizes customer-centricity and innovation, offering comprehensive technical support and regular software updates to ensure continuous quality improvement and stability. They engage in strategic partnerships, such as with iCAD and Intelerad, to expand accessibility and integrate their AI solutions into broader breast health ecosystems. Densitas is committed to developing scalable and sustainable breast health solutions, continuously expanding their product portfolio to address evolving needs in breast cancer screening.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.